Validation: Page 2

Veracyte genomic test classifies lung cancer risk in study
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Veracyte's Percepta Genomic Sequencing Classifier (GSC) can accurately classify lung cancer risk from inconclusive samples taken in a bronchoscopy.
July 19, 2022
2022 04 18 13 42 3384 Dna Genome Gene Targeted 400
Medial EarlySign, Roche partner on lung cancer detection
The goal is to deliver validated clinical machine learning models for lung cancer detection with EarlySign's LungFlag technology. The technology uses a variety of signals, including basic demographic, medical, drug, and routine clinical lab data.
July 7, 2022
2022 01 25 22 49 5402 Lung 3 D 400
Mainz Biomed launches biomarker study for ColoAlert
Acquired by Mainz from the Université de Sherbrooke in Quebec in January, the mRNA biomarkers had been shown in prior studies to provide high sensitivity and specificity for detecting colon cancer and precancerous lesions.
June 27, 2022
2019 11 04 19 56 0311 Colorectal Cancer 400
Oxford BioDynamics launching oncology test in the U.K.
The company noted that its EpiSwitch CiRT blood test predicts the likelihood of a cancer patient's response to ICI therapeutics that include anti-PD-L1 and anti-PD-1 immunotherapies.
June 20, 2022
2022 06 09 19 27 4366 Cell Gene Therapy Dna 400
Veracyte announces evidence supporting thyroid genomic test
When the test deems a nodule suspicious, the patient's risk of malignancy is consistent and higher than that reported in the classifier's original clinical validation study, the firm said.
June 19, 2022
2017 01 30 16 54 10 442 Thyroid 400
Flagship Biosciences announces study validating assay
The Broomfield, CO-based company said its digital PD-L1 assay provides solutions to current challenges with the use of immunohistochemistry (IHC) to determine the level of PD-L1 expression in tumor tissues.
June 13, 2022
2022 06 14 19 48 7507 Immunotherapy Cancer Cell 400
Most Popular
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Quest Diagnostics offers suite of services for transplant patients and living donors
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Rapid nirmatrelvir treatment in study reduced long-COVID risk
Applied DNA Sciences, EvviVax announce cancer vaccine data
The firms noted that the study, published on June 6, found that two LinearDNA therapeutic cancer vaccines elicited a strong immune and specific antitumor response in mouse models using electro-gene-transfer as the delivery method.
June 6, 2022
2021 02 17 17 07 0976 Dog Paw Hand 400
Bristol Myers Squibb promotes ctDNA liquid biopsy study
BMS scientists demonstrated that Predicine's PredicineAtlas liquid biopsy next-generation sequencing (NGS) assay outperformed four other tests in detection sensitivity, specificity, accuracy, and reproducibility. The Precidine assay also proved capable of identifying gene deletion or copy number reductions in the study, Bristol Myers Squibb said.
May 17, 2022
2019 04 22 18 53 8505 Lab Blood Liquid Samples 400
Delfi enrolls first participants in liquid biopsy lung cancer trial
The CASCADE-LUNG study is expected to enroll 15,000 patients and aims to clinically validate Delfi's test, which detects a blood-based signal of undiagnosed lung cancer. It is a prospective, multicenter trial that will enroll participants at the time of their low-dose computed tomography (LDCT) lung cancer scans.
May 8, 2022
2019 09 09 20 46 2283 Lung Cancer 400
Guardant releases colorectal cancer blood test
In a validation effort using 309 patient samples (including 92 with colorectal cancer), the Shield test showed a sensitivity of 91% and a specificity of 92% for detecting colorectal cancer. It is intended for adults 45 years and older who are not current with screening recommendations, are asymptomatic, and are at average risk for the disease.
May 1, 2022
2021 01 12 23 44 3780 Blood Test Samples Lab 400
Immunovia applies to AMA for PLA code
The company has touted the results of a study showing that the test detected stage I/II pancreatic ductal adenocarcinoma with 99% specificity and 89% sensitivity.
April 17, 2022
2020 02 14 01 40 9390 Cancer Pancreatic 400
Fosun's COVID-19 test approved in China
The test has high sensitivity and specificity, a strong anti-interference ability, and no cross-reactivity among viruses and bacteria, Fosun said.
April 14, 2022
2021 01 11 17 03 4617 Covid Diagnostic Test Kit 400
Previous Page
Page 2 of 8
Next Page